Vanda Pharmaceuticals Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Washington, DC
VNDA chart
What traders are saying about $VNDA
Latest postsVanda Pharmaceuticals Inc. news
- Vanda eyes GLP-1 nausea indication with Nereus phase 3 win in hand
Fierce Pharma ·
- BlackRock Portfolio Management reports ownership above 5% in Vanda Pharmaceuticals (VNDA).
Stock Titan ·
- Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
Benzinga ·
- Vanda Pharmaceuticals posts positive results from NEREUS tradipitant study 3601
Traders Union ·
- Vanda's NEREUS cuts GLP-1 induced vomiting in Phase 3 Study 3601
Dealroom ·
- Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial
HCPLive ·
- Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Yahoo Finance ·
- Charcot-Marie-Tooth Disease Market is Projected to Grow by 2036 Owing to the Development of Novel Therapies | DelveInsight
StreetInsider ·
- Vanda Pharmaceuticals Inc expected to post a loss of 68 cents a share - Earnings Preview
TradingView ·
- Women's Tennis Association - Official Website
WTA Tennis ·
- Vanda Pharmaceuticals stock: Vanda sets October 28 results date for Vanda Pharmaceuticals stock
ad-hoc-news.de ·
- Vanda Pharmaceuticals Inc. Estimates – NASDAQ:VNDA
TradingView ·
Vanda Pharmaceuticals Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M |
| Net income | -$220.5M | -$18.9M | $2.5M | $6.3M |
| Diluted EPS | $-3.74 | $-0.33 | $0.04 | $0.11 |
| Total assets (year end) | $488.9M | $656.2M | $648.4M | $634.2M |
| Cash and equivalents (year end) | $84.9M | $102.3M | $135.8M | $135.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Vanda Pharmaceuticals Inc.
- Ticker
- VNDA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Washington, DC
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1347178
Frequently asked questions
What exchange is Vanda Pharmaceuticals Inc. listed on?
Vanda Pharmaceuticals Inc. trades on the Nasdaq under the ticker symbol VNDA.
What industry is Vanda Pharmaceuticals Inc. in?
Vanda Pharmaceuticals Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Vanda Pharmaceuticals Inc. headquartered?
Vanda Pharmaceuticals Inc.'s business address on file with the SEC is in Washington, DC.
When does Vanda Pharmaceuticals Inc.'s fiscal year end?
Vanda Pharmaceuticals Inc.'s fiscal year ends on December 31.
How much revenue did Vanda Pharmaceuticals Inc. report?
Vanda Pharmaceuticals Inc. reported $216.1M in revenue for calendar year 2025, according to its SEC filings.